REPLICATION REPAIR DEFICIENT

Clinical trials for REPLICATION REPAIR DEFICIENT explained in plain language.

Never miss a new study

Get alerted when new REPLICATION REPAIR DEFICIENT trials appear

Sign up with your email to follow new studies for REPLICATION REPAIR DEFICIENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Promising drug combo targets aggressive brain cancers in youth

Disease control Not yet recruiting

This study is for adolescents and young adults (ages 12-39) newly diagnosed with aggressive brain tumors called high-grade glioma or DIPG. The goal is to see if a combination of two immunotherapy drugs (relatlimab and nivolumab, sold as Opdualag) is safe and tolerable when given …

Matched conditions: REPLICATION REPAIR DEFICIENT

Phase: PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control

Last updated Jun 27, 2026 13:07 UTC

REPLICATION REPAIR DEFICIENT

Get alerted when new REPLICATION REPAIR DEFICIENT trials appear

Promising drug combo targets aggressive brain cancers in youth